Abstract
Epigenetics, the study of heritable changes in gene expression not involving changes in DNA sequence, plays a key role in the pathogenesis of cancers like myelodysplastic syndrome (MDS) and leukemias. This chapter discusses the role of epigenetics in the pathogenesis of MDS and leukemias. The study of epigenetics has impacted pharmacology leading to the development of a new class of drugs, epigenetic drugs, which attempt to reverse epigenetic changes in clinical disorders. At present, most work is being done on two categories of epigenetic drugs : DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi). The chapter discusses the use of epigenetic drugs in the treatment of MDS and leukemias.
Keywords: Epigenetic drug, histone, leukemia, methylation, myelodysplastic syndrome, RNA.
About this chapter
Cite this chapter as:
Jacob Peedicayil ;Epigenetic Drugs in Myelodysplastic Syndrome and the Leukemias, Frontiers in Clinical Drug Research: Hematology (2014) 1: 42. https://doi.org/10.2174/9781608058587114010004
DOI https://doi.org/10.2174/9781608058587114010004 |
Print ISSN 2352-3239 |
Publisher Name Bentham Science Publisher |